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Abstract Stopped-flow kinetics showed that the inhibition of
the lysosomal cysteine proteinase, cathepsin B, by its endogenous
inhibitor, cystatin C, occurs by a two-step mechanism, in which
an initial, weak interaction is followed by a conformational
change. The initial interaction most likely involves binding of the
N-terminal region of the inhibitor to the proteinase. Considerable
evidence indicates that the subsequent conformational change is
due to the inhibitor displacing the occluding loop of the
proteinase that partially obscures the active site. The presence
of this loop, which allows the enzyme to function as an
exopeptidase, thus complicates the inhibition mechanism, render-
ing cathepsin B much less susceptible than other cysteine
proteinases to inhibition by cystatins.
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1. Introduction
Cathepsin B is a mammalian, papain-like lysosomal cys-
teine proteinase, the main function of which is to degrade
proteins inside lysosomes. The extralysosomal action of ca-
thepsin B, as well as that of other lysosomal cysteine protei-
nases, is regulated by protein inhibitors of the cystatin super-
family. Cystatin C, an important such inhibitor in most
tissues, is a non-glycosylated protein with Mr V13 400, con-
taining two disul¢de bonds [1^3]. Like other cystatins, cystatin
C inhibits its target proteinases by trapping them in a tight
complex, in which a binding region of the inhibitor compris-
ing three di¡erent regions of the polypeptide chain interacts
with the proteinase active-site cleft [4,5].
All rapid-kinetics studies at high inhibitor concentrations
done so far of the binding of cystatin C and other cystatins
to cysteine proteinases are compatible with the enzyme-inhib-
itor complexes being formed by a one-step, reversible bimo-
lecular reaction [6^12]. This behavior is in agreement with
computer docking experiments based on the X-ray structures
of chicken cystatin and papain, which show that a complex
can be formed with negligible conformational adaptations of
either protein [4]. In contrast, the X-ray structure of cathepsin
B [13] suggests that cystatins may react in a di¡erent manner
with this enzyme. Cathepsin B thus has an occluding loop,
comprising residues 104^126, that partially blocks the active
site, thereby modulating the substrate- and inhibitor-binding
properties of the enzyme [14]. In particular, by limiting access
of substrates to the primed sites of the active-site cleft, this
loop enables cathepsin B to function as an exopeptidase, re-
moving C-terminal dipeptides, in addition to the usual endo-
peptidase action of papain-like cysteine proteinases [13,14].
Docking experiments with chicken cystatin suggested that
the occluding loop would interfere with the binding of cysta-
tins but that this interference could be reduced by the loop
being displaced during the binding [13]. Analyses of the inter-
action of N-terminally truncated or engineered variants of
cystatin C and chicken cystatin with cathepsin B further in-
dicated that this displacement is facilitated by initial binding
of the N-terminal region of the inhibitor to the S2 and pre-
sumably also the S3 subsite of cathepsin B [15^21]. Both these
observations thus imply that the mechanism of cystatin C
binding to cathepsin B is more complicated than a simple
one-step reaction.
In this work we show by stopped-£ow £uorimetry that the
binding of human recombinant cystatin C to human recombi-
nant cathepsin B is indeed best described by a two-step reac-
tion mechanism, involving an initial weak interaction followed
by a conformational change. We also present evidence that
the occluding loop is displaced during the binding by studies
of the interaction of cystatin C with a mutant of cathepsin B,
in which a £uorescent probe had been introduced in the loop
by replacement of His-111 with Trp.
2. Materials and methods
2.1. Proteins
Human recombinant cystatin C was produced and isolated as de-
scribed in [8,22]. Human wild-type procathepsin B and the pro-form
of the H111W mutant were expressed as alpha factor fusion con-
structs in the methylotropic yeast, Pichia pastoris. In this system the
proenzymes are secreted into the culture medium. Autoprocessing was
initiated by dialysis of the medium to pH 5.0, and the resultant ma-
ture, active forms were puri¢ed by ion exchange chromatography [14].
The substitution H111W was introduced by site-directed mutagenesis.
As previously [17], for both the wild-type and mutant proteins the
consensus sequence for asparagine-linked oligosaccharide substitution
was removed through the modi¢cation S115A (NGS to NGA). Both
enzyme forms were activated with 0.5 mM dithiothreitol for 5 min at
25‡C before measurements. The puri¢cation, storage and activation of
papain have been reported elsewhere [23]. The inactivated papain
forms, S-(methylthio)-papain and S-(carbamoylmethyl)-papain, were
obtained as in previous work [8,24].
Protein concentrations were determined by absorption measure-
ments at 280 nm. Molar absorption coe⁄cients of 11 100 and 56 000
M31 cm31 have been determined previously for cystatin C and pa-
pain, respectively [8,25]. Molar absorption coe⁄cients of 63 000 and
69 000 M31 cm31 were calculated for wild-type and H111W-cathepsin
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B, respectively, from the amino acid sequence [26,27] by the method
of Pace et al. [28].
2.2. Experimental conditions
All experiments were performed at 25‡C in 50 mM MES, 100 mM
NaCl, 100 WM EDTA, 0.1% (w/v) poly(ethyleneglycol), 0.5 mM di-
thiothreitol, pH 6.0.
2.3. Activity of inhibitor and enzymes
The fraction of active inhibitor in the cystatin C preparation used
was determined by titration with S-(methylthio)-papain, monitored by
the decrease of tryptophan £uorescence accompanying the interaction,
as described previously [8,24]. The fraction of enzyme in the prepara-
tions of wild-type and H111W-cathepsin B that was active in binding
to cystatin C was determined by titrations of enzyme with inhibitor,
monitored by the residual enzyme activity. Cathepsin B at a concen-
tration of 1 WM was incubated at 25‡C for 5 min with cystatin C at
concentrations ranging from 0.1 to 2.0 WM. The samples were then
diluted 1000-fold into a 10 WM solution of the £uorogenic substrate,
carbobenzoxy-L-arginyl-L-arginine 4-methylcoumaryl-7-amide (Pep-
tide Institute, Osaka, Japan), and the residual cathepsin B activity
was obtained from measurements of the initial £uorescence increase
with time at excitation and emission wavelengths of 370 and 440 nm,
respectively. The residual activity was plotted against the molar ratio
of inhibitor to enzyme, and the apparent inhibition stoichiometry was
obtained by extrapolation of the linear portion of this plot to the
abscissa.
2.4. Kinetic measurements
The kinetics of association of cystatin C with wild-type or H111W-
cathepsin B were analyzed at 25.0 þ 0.1‡C in an SX-17MV stopped-
£ow instrument (Applied Photophysics, Leatherhead, UK), as de-
scribed previously [6,8,21]. All experiments were done under pseudo-
¢rst-order conditions with a 10-fold molar ratio of inhibitor to en-
zyme, based on total protein concentrations. The reactions were moni-
tored by changes of tryptophan £uorescence, measured at an excita-
tion wavelength of 280 nm and with an emission cuto¡ ¢lter with 50%
transmission at V320 nm.
The rate of dissociation of complexes between cystatin C and wild-
type or H111W-cathepsin B was measured by a displacement method
[6,17,19]. Cystatin C dissociating from 200 nM complex was essen-
tially irreversibly trapped by an excess (2^4 WM) of the inactive papain
derivative, S-(carbamoylmethyl)-papain, which binds about ¢ve-fold
more tightly to cystatin C than cathepsin B [19]. The rate of the
concomitant release of the enzyme was monitored by continuous ab-
sorption measurements at 410 nm of the cleavage of the chromogenic
substrate, N-K-benzoyl-L-arginine p-nitroanilinide (350 WM; Sigma,
St. Louis, MO, USA).
3. Results
3.1. Activity of inhibitor and enzymes
Titrations, monitored by tryptophan £uorescence, of S-
(methylthio)-papain with cystatin C gave a stoichiometry of
binding of inhibitor to enzyme of 1.01 þ 0.03 (range, n = 2), i.e.
the inhibitor was fully active in binding papain, as established
previously [8]. Wild-type and H111W-cathepsin B were shown
by measurements of residual activity in titrations with cystatin
C to be 46 þ 1% (S.E., n = 4) and 73% (n = 1) active in binding
to the inhibitor, respectively.
3.2. Association kinetics
The kinetics of binding of cystatin C to wild-type or
H111W-cathepsin B were analyzed by stopped-£ow measure-
ments, monitored by the changes of intrinsic £uorescence ac-
companying the binding. The reaction with wild-type cathep-
sin B resulted in V4% £uorescence decrease under the
conditions of the stopped-£ow measurements, a value com-
parable to the V6% decrease obtained previously for the re-
action of cystatin C with recombinant rat cathepsin B [17]. In
contrast, a £uorescence increase ofV11% was observed in the
reaction of cystatin C with H111W-cathepsin B. The £uores-
cence changes were satisfactorily ¢tted to a single exponential
function at all inhibitor concentrations. The resulting pseudo-
¢rst-order rate constants showed a hyperbolic dependence on
inhibitor concentration for both wild-type and H111W-ca-
thepsin B (Fig. 1), indicating a two-step binding mechanism
for both enzyme variants. In the simplest such mechanism
compatible with exponential progress curves [29], a weak com-
plex (PI) between proteinase (P) and inhibitor (I) in a rapid
equilibrium and with a dissociation constant K1 is established
in the initial step. In the second step, this complex is convert-
ed to the ¢nal, stable complex (PI*) by a reversible conforma-
tional change with rate constants k2 and k32 (Scheme 1).
The data for both enzyme forms could be well ¢tted by
non-linear least-squares regression to the equation for this
mechanism [29],
kobs  k2IK1  I  k32 1
(Fig. 1), indicating that the mechanism in Scheme 1 is a sat-
isfactory description of the binding process. Values for K1 and
k2 were derived from these analyses (Table 1), whereas k32
was experimentally indistinguishable from zero for both en-
zyme forms. The bimolecular association rate constant, kon,
which is equal to k2/K1 for the mechanism in Scheme 1 [29],
was essentially identical for the two enzyme variants (Table 1)
and comparable to the values of 1.1U106^1.4U106 M31 s31
determined previously for the interaction between cystatin C
and rat cathepsin B [17,18].
3.3. Dissociation kinetics
The overall dissociation rate constant of the cystatin C-
cathepsin B interaction, koff , which is equal to k32 for the
mechanism in Scheme 1 [29], was determined by a displace-
ment procedure (Table 1). The value obtained for wild-type
cathepsin B is comparable to those of 3.1U1034^3.5U1034
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Fig. 1. Observed pseudo-¢rst-order rate constants, kobs, for the bind-
ing of cystatin C to wild-type cathepsin B and H111W-cathepsin B
as a function of cystatin C concentration. (a) Wild-type cathepsin
B; (b) H111W-cathepsin B. Error bars represent þ S.E., calculated
from 12^25 individual measurements. The solid lines are the non-
linear least-squares regression ¢ts of the data to Eq. 1.
Scheme 1.
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s31 measured or calculated for the complex between cystatin
C and rat cathepsin B [17,18]. The overall dissociation equi-
librium constant, Kd, was calculated as koff /kon (Table 1). The
Kd for the wild-type enzyme is similar to the values of 0.17^
0.26 nM reported previously for the interaction of cystatin C
with human liver or recombinant cathepsin B [14,20,30] and
also to the Kd of 0.28^0.30 nM measured for the binding of
the inhibitor to rat cathepsin B [17,18]. The data for H111W-
cathepsin B show that substitution of His-111 by Trp slightly
weakened the interaction with cystatin C, predominantly as a
result of an increased dissociation rate constant.
4. Discussion
These results show that the inhibition of cathepsin B by its
endogenous inhibitor, cystatin C, is best described as a two-
step reaction, in which an initial, weak interaction between the
two proteins with a dissociation constant of about 50 WM is
followed by a conformational change with a rate constant of
about 120 s31, leading to tighter binding. The initial interac-
tion most likely involves binding of the N-terminal region of
the inhibitor to the proteinase, in particular to the S2 and S3
subsites [4,17,18,20,21]. This conclusion is indicated by the
decreased rate of association of cystatin C with cathepsin B,
but not with other cysteine proteinases, on removal of the N-
terminal region of the inhibitor [17]. In the reaction with
cathepsin B, the N-terminal region of cystatin C thus appears
to act as a guide directing the inhibitor to the appropriate
binding position on the enzyme [21].
The conformational change following the initial binding
step presumably is due mainly to cystatin C displacing the
occluding loop of cathepsin B that partially obscures the ac-
tive site of the enzyme. Modelling experiments showed that
this loop would interfere substantially with the binding of
cystatin C, in particular colliding with the second hairpin
loop of the inhibitor [13]. However, much of the steric hin-
drance could be released by tilting and simultaneous rotation
of the inhibitor and displacement of the loop. Such mobility
of the occluding loop is demonstrated by the X-ray structure
of procathepsin B, in which the loop is pushed aside by the
propeptide, which binds to the active site and thereby keeps
the enzyme in an inactive state [31^33]. That the occluding
loop of cathepsin B is displaced in the reaction with cystatin C
is also indicated by the higher forward rate constant of the
conformational change step observed in this work for the
binding of cystatin C to H111W-cathepsin B than for the
binding to the wild-type enzyme. This e¡ect presumably is
due to the mutation disrupting interactions between the oc-
cluding loop and the rest of the protein [13,14], thereby facil-
itating movement of the loop. This proposal is in agreement
with recent studies showing that elimination of an electrostatic
interaction between the occluding loop and the main body of
cathepsin B leads to an increased a⁄nity of the enzyme for
chicken cystatin, presumably due to loop displacement being
facilitated [33]. However, the mutated loop having a Trp res-
idue does not behave substantially di¡erently from the wild-
type loop, as indicated by the only moderately decreased af-
¢nity of cystatin C for H111W-cathepsin B. The small reduc-
tion in a⁄nity most likely is due to the binding of the inhib-
itor being somewhat hampered by the larger size of the indole
ring than of the original imidazole ring, leading to an in-
creased dissociation rate constant. The £uorescence increase
observed on binding of H111W-cathepsin B to cystatin C,
di¡erent from the decrease seen for the wild-type proteinase,
is also consistent with the Trp side chain having moved on
formation of the complex, probably to a more hydrophobic
environment. Further evidence for the need for the loop to be
displaced in the reaction with cystatins is provided by the
substantially increased a⁄nity of cystatin C for a form of
cathepsin B in which the occluding loop had been deleted
by protein engineering [14].
Previous rapid-kinetics studies have indicated that reactions
of other cysteine proteinases than cathepsin B with cystatin C
and similar cystatins proceed in one step and generally result
in complexes with higher a⁄nity [6^12]. The evolution of the
occluding loop, which allows cathepsin B to function as an
exopeptidase [13,14], has thus had the concomitant disadvant-
age that the enzyme is less e⁄ciently regulated by endogenous
inhibitors as a result of a more complicated inhibition mech-
anism and consequent weaker binding.
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